FPT-CORPORATION
15.4.2024 11:39:33 CEST | Business Wire | Press release
FPT Corporation (FPT) announced its strategic directions for the 2024-2026 period at the 2024 Annual General Meeting, with five focused areas defined as Artificial Intelligence (AI), Automotive, Semiconductor, Digital Transformation, and Green Transformation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415401317/en/
FPT’s 2024 Annual General Meeting was held in Hanoi, Vietnam (Photo: Business Wire)
According to FPT Chairman Dr. Truong Gia Binh, these five areas have shaped the course of modern history and will continue to be of critical importance in decades to come. In Vietnam’s case, they have been instrumental in solidifying the country's position as a global hub for business and innovation.
In this direction, AI remains at the heart of FPT's development strategy, aiming to serve at least 50% of Vietnamese citizens and 300 million global citizens. The Corporation is committed to expanding its AI ecosystem, continuing strategic partnerships with the world’s leading names, and embedding AI into all of its solutions and services. FPT's Generative AI and Visual AI solutions will also be tailored to cater to specific industry needs.
In the automotive sector, following the launch of FPT Automotive in 2023, FPT’s investment lies in the development of intelligent solutions, offering comprehensive automotive services. FPT Automotive aims to transition from software outsourcing to technical design for software-defined vehicles, targeting a 50% annual growth rate and a revenue of 1 billion USD by 2030.
With regard to the semiconductor industry, FPT has a dual target: supplying chips to more global customers and enhancing workforce development. FPT Chairman emphasized the Corporation’s aspiration to turn Vietnam into a powerhouse in semiconductor, mirroring its past success with software export. According to Dr. Truong Gia Binh, FPT will “fully integrate Vietnam into the global semiconductor ecosystem”. “We will establish joint ventures for IC design and testing and partner with local authorities to attract foreign investment in the semiconductor sector,” he added.
For the 2024-2026 period, FPT also aims to accelerate digital transformation, promote green transformation with smart transformation initiatives, further establishing its position as a leading partner for global businesses in these areas.
To accelerate these goals, mergers and acquisitions (M&A) will continue to be FPT’s strategic focus, especially in supporting the automotive sector. “FPT wants to acquire companies that manufacture and design cars,” said Dr. Binh. Its M&A activities this year will center around the US and expand to Japan, South Korea, Singapore, and Europe. These are built upon successful investments and M&A deals in 2023, notably with NAC, Cardinal Peak, AOSIS, Landing AI, and Intertec International.
In 2023, FPT exceeded its targets, recording an increase of 19.6% in revenue and 20.1% in pre-tax profit compared to the previous year. The year 2023 also witnessed a historic milestone for FPT, with the revenue from IT services for the global market exceeding $1 billion, generated by its subsidiary FPT Software. In 2024, FPT aims for a 17.5% revenue growth and an 18.2% increase in profit before tax.
Pham Minh Tuan, FPT EVP and FPT Software CEO, said: “Starting from 2024, the Corporation remains committed to deep investment, focusing on the development of high-value technologies like AI and Data, and ventures in rapidly growing sectors such as Automotive, Healthcare, Banking, Insurance, and Energy. We are determined to elevate our standards and surpass expectations to become a world-class company.”
About FPT Corporation and FPT Software
FPT Corporation is a global technology corporation and a leader in consulting, providing, and deploying technology and telecommunications services and solutions. It records a global workforce of 48,000+ and total revenue of $2.17 billion (2023).
FPT Software, a subsidiary of FPT Corporation, is a global technology and IT services provider headquartered in Vietnam, with $1 billion in revenue (2023) and over 30,000 employees in 30 countries.
The company champions complex business opportunities and challenges with its world-class services in Advanced Analytics, AI, Digital Platforms, Cloud, Hyperautomation, IoT, Low-code, and so on. It has partnered with over 1,000+ clients worldwide, 91 of which are Fortune Global 500 companies in Aviation, Automotive, Banking, Financial Services and Insurance, Healthcare, Logistics, Manufacturing, Utilities, and more. For more information, please visit https://fptsoftware.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415401317/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom